Co-Diagnostics (CODX) Releases Q4 2025 Earnings: Revenue Down, Net Loss Widens

Co-Diagnostics Inc. (CODX) reported quarterly results showing revenue of $263,922, down 27.98% year‑over‑year.

Gross profit was $121,526, a decline of 214.93% versus the prior year.

Operating loss widened to -$26.5 million, a 122.91% increase in the loss year‑over‑year.

Net loss attributable to common shareholders was -$25.7 million, worsening 133.39% year‑over‑year.

Diluted loss per share stood at -$16.65 per share, a change of 4,525.00% year‑over‑year.

Cash used in operating activities totaled -$5.9 million, down 28.26% year‑over‑year.

Purchases of property, plant and equipment were -$75,105, up 2.90% year‑over‑year.

Cash and cash equivalents increased to $11.9 million, a rise of 304.71% year‑over‑year.

Total liabilities declined to $4.1 million, down 57.54% year‑over‑year.

Cost of sales for the quarter was $142,396, a decrease of 44.17% year‑over‑year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Co-Diagnostics Inc. Hedge Fund Activity

We have seen 13 institutional investors add shares of Co-Diagnostics Inc. stock to their portfolio, and 21 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TOWER RESEARCH CAPITAL LLC (TRC) added 12,988 shares (+25976.0%) to their portfolio in Q4 2025, for an estimated $65,693
VANGUARD GROUP INC added 6,772 shares (+11.9%) to their portfolio in Q4 2025, for an estimated $34,252
JANE STREET GROUP, LLC added 5,956 shares (+287.0%) to their portfolio in Q4 2025, for an estimated $30,125
HRT FINANCIAL LP removed 4,976 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,168
RENAISSANCE TECHNOLOGIES LLC removed 4,573 shares (-15.8%) from their portfolio in Q4 2025, for an estimated $23,130
GEODE CAPITAL MANAGEMENT, LLC added 4,305 shares (+40.4%) to their portfolio in Q4 2025, for an estimated $21,774
VIRTU FINANCIAL LLC removed 4,217 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $21,329

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Co-Diagnostics Inc. Analyst Ratings

Wall Street analysts have issued reports on $CODX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

D. Boral Capital issued a "Buy" rating on 10/28/2025

To track analyst ratings and price targets for Co-Diagnostics Inc., check out Quiver Quantitative's $CODX forecast page.

Co-Diagnostics Inc. Price Targets

Multiple analysts have issued price targets for $CODX recently. We have seen 2 analysts offer price targets for $CODX in the last 6 months, with a median target of $2.25.

Here are some recent targets:

Jason McCarthy from Maxim Group set a target price of $1.5 on 11/26/2025
Jason Kolbert from D. Boral Capital set a target price of $3.0 on 10/28/2025